Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa

BMC Public Health

Estelle V Lambert³  Naomi S Levitt⁴  Joel A Dave²  Sacha J West¹  Mweete D Nglazi³ 

[1] Department of Sport Management, Human Performance Laboratory, Cape Peninsula University of Technology, Cape Town, South Africa;Division of Diabetic Medicine and Endocrinology, Department of Medicine, University of Cape Town, Cape Town, South Africa;MRC/UCT Research Unit for Exercise Science and Sports Medicine, Department of Human Biology, University of Cape Town, Cape Town, South Africa;Chronic Disease Initiative for Africa (CDIA), Cape Town, South Africa

关键词: EQ-5D;    Health outcomes;    HIV or AIDS;    Health related quality of life;   

Others  :  866322
DOI  :  10.1186/1471-2458-14-676

 received in 2013-12-20, accepted in 2014-06-19,  发布年份 2014

【 摘 要 】

Background

Health related quality of life (HRQoL) is an important outcome helping to understand the impact of antiretroviral therapy (ART). We examined and compared the HRQoL in relation to ART status among HIV-infected patients in a public sector service in Cape Town, South Africa. In addition, we aimed to examine the relationship between ART status and HRQoL according to CD4 count strata.

Methods

A cross sectional study sample of 903 HIV-infected patients who were categorized as not receiving ART (ART-naïve) or receiving first-line ART for > 6 months (ART). HRQoL outcomes were compared in the two groups. HRQoL was assessed using the EQ-5D (five domains) and Visual Analogue Scale (EQ-5D VAS).

Results

Of the total sample, 435 were categorised as ART naïve (76% women) and 468 were on ART (78% women). There were no significant associations between groups for most of the EQ-5D domains, however ART-naïve experienced a significantly greater problem with mobility than the ART group. Being ART-naïve (adjusted odds ratio (aOR) 3.08 95% confidence interval (CI) 1.63- 7.89) and obese 2.78 (95% CI 1.24- 6.22) were identified as predictors for increased mobility problems in multivariate analysis. In addition, receiving ART (5.61 difference; 95% CI 2.50 - 8.72) and having some source of income (4.76; 95% CI 1.63 -7.89) were identified as predictors for a higher EQ-5D VAS score. When grouped according to CD4 count strata, there were no significant difference between groups for most of the EQ-5D domains, however the ART-naïve group indicated having significantly greater problems under the CD4 count of >500 cells/μL in the anxiety/depression domain (22.4% vs 8.8%, p = 0.018) and significantly lower EQ-5D VAS scores under the CD4 counts of ≤200 cells/μL (median 80 (IQR 60–90) vs 90 (IQR 80–100), p = 0.0003) and 201–350 cells/μL (median 80 (IQR 70–90) vs 90 (80–100), p = 0.0004) compared to ART group.

Conclusions

HRQoL (self-rated health state) was improved with ART use, including those with immunocompromised status, which may be relevant to the public sector ART program in South Africa.

【 授权许可】

   
2014 Nglazi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]UNAIDS: Report on the global AIDS rpidemic 2013. Joint United Nations Programme on HIV/AIDS. 2013. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf webcite
• [2]World Health Organization: Global update on HIV treatment 2013: results, impact and opportunities: WHO report in partnership with UNICEF and UNAIDS. Geneva: World Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734_eng.pdf webcite
• [3]Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA: HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. Aids 2001, 15:1811-1822.
• [4]Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PWF: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clinical Infectious Diseases 2001, 32:130-139.
• [5]Bradbury RA, Samaras K: Antiretroviral therapy and the human immunodeficiency virus–improved survival but at what cost? Diabetes Obes Metab 2008, 10:441-450.
• [6]Mutimura E, Stewart A, Rheeder P, Crowther NJ: Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 46:451-455.
• [7]Igumbor J, Stewart A, Holzemer W: Comparison of the health-related quality of life, CD4 count and viral load of AIDS patients and people with HIV who have been on treatment for 12 months in rural South Africa. Sahara J 2013, 10:25-31.
• [8]McInerney PA, Ncama BP, Wantland D, Bhengu BR, McGibbon C, Davis SM, Corless IB, Nicholas PK: Quality of life and physical functioning in HIV-infected individuals receiving antiretroviral therapy in KwaZulu-Natal, South Africa. Nurs Health Sci 2008, 10:266-272.
• [9]Pitt J, Myer L, Wood R: Quality of life and the impact of drug toxicities in a South African community-based antiretroviral programme. J Int AIDS Soc 2009, 12:5. BioMed Central Full Text
• [10]Louwagie GM, Bachmann MO, Meyer K, Booysen FR, Fairall LR, Heunis C: Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study. BMC Public Health 2007, 7:244. BioMed Central Full Text
• [11]Jelsma J, Maclean E, Hughes J, Tinise X, Darder M: An investigation into the health-related quality of life of individuals living with HIV who are receiving HAART. AIDS care 2005, 17:579-588.
• [12]Wouters E, Van Loon F, Van Rensburg D, Meulemans H: State of the ART: clinical efficacy and improved quality of life in the public antiretroviral therapy program, Free State province, South Africa. AIDS Care 2009, 21:1401-1411.
• [13]Bhargava A, Booysen Fle R: Healthcare infrastructure and emotional support are predictors of CD4 cell counts and quality of life indices of patients on antiretroviral treatment in Free State Province, South Africa. AIDS Care 2010, 22:1-9.
• [14]Anastos K, Lu D, Shi Q, Tien PC, Kaplan RC, Hessol NA, Cole S, Vigen C, Cohen M, Young M, Justman J: Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr 2007, 45:34-42.
• [15]Domingos H, Cunha RV, Paniago AM, Martins DM, Elkhoury EB, Souza AS: Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. Braz J Infect Dis 2009, 13:130-136.
• [16]van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atte EF, Reid T: Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda. Trans R Soc Trop Med Hyg 2010, 104:148-153.
• [17]Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT: Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary. J Infect Dis 2007, 196(Suppl 3):S449-456.
• [18]Ait-Mohand H, Bonmarchand M, Guiguet M, Slama L, Marguet F, Behin A, Amellal B, Bennai Y, Peytavin G, Calvez V, Pialoux G, Murphy R, Katlama C: Viral efficacy maintained and safety parameters improved with a reduced dose of stavudine: a pilot study. HIV Med 2008, 9:738-746.
• [19]Cournil A, Coudray M, Kouanfack C, Essomba CN, Tonfack CA, Biwole-Sida M, Delaporte E, Bork K, Laurent C: Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Antivir Ther 2010, 15:1039-1043.
• [20]Pedrol E, Martin T, del Pozo MA, Flores J, Sanz J, Carton JA, Jusdado JJ, Arazo P, Ribera E, Deig E: Efficacy and safety of a reduced-dose of stavudine in HIV-infected patients under immunological and virological stable conditions. Med Clin (Barc) 2007, 129:361-365.
• [21]Hanvanich M, Prasanthai V, Riengchan P, Arunyingmongkol K, Intalapaporn P, Hiransuthikul N, Suankratay C, Kulwichit W: Reduction of D4T Dosage Improves Lipoatrophy Without Virologic Failure. In Proceedings of the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris; 2003. Abstract no.749
• [22]Delpierre C, Cuzin L, Alvarez M, Khatibi S, Bonnet E, Obadia M, Massip P: Lowering stavudine dosages does not compromise anti-viral efficacy in HIV-1 infected patients. Proceedings of the 9th European AIDS Conference 2003. Abstract no.262
• [23]Koegl C, Wolf E, Postel N, Buchberger A, Ruemmelein N, Jaegel-Guedes E, Jaeger H: Low Dose Stavudine: As Effective as Standard Dose but Less Side Effects. Proceedings of the 9th European AIDS Conference 2003. Abstract no.284
• [24]Urbina A, Jibilian A, Nibbe Y, Maa JF, Wang S: Long Term Use of Low dose Stavudine is Effective and Well Tolerated. Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment 2005. Abstract no. TuPe2.2B31
• [25]Ribera E, Paradiñeiro JC, Domingo P, Sauleda S, Luque S, Garcia-Arumi E, Feijoo M, Fontanet A, Falco V, Crespo M, Ocana I, Sureda D, Planas M, Pahissa A: A Randomized Study Comparing the Efficacy and Tolerability of Lowdose versus Standard-dose Stavudine in Antiretroviral-naïve patients (ETOX Study). Proceedings of the 3rd IAS Conference on HIV Pathogenesis and Treatment 2005. Abstract no. TuPe2.4 C10
• [26]World Health Organization: Antiretroviral therapy for HIV infection in adults and adoloscents. Geneva: World Health Organization; 2010.
• [27]Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama 2004, 292:191-201.
• [28]World Health Organization: March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:Recommendations for a public health approach. Geneva: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/104264/1/9789241506830_eng.pdf webcite
• [29]Jouquet G, Bygrave H, Kranzer K, Ford N, Gadot L, Lee J, Hilderbrand K, Goemaere E, Vlahakis N, Trivino L, Makakole L, Cleary S: Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. J Acquir Immune Defic Syndr 2011, 58:e68-74.
• [30]National Department of Health: National Antiretroviral Treatment Guidelines. Pinetown, South Africa: Jacana Publishers; 2004.
• [31]Dave JA, Lambert EV, Badri M, West S, Maartens G, Levitt NS: Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr 2011, 57:284-289.
• [32]Harrison GG, Buskirk ER, Carter JEL, Johnston FE, Lohman TG, Pollock ML, Roche AF, Wilmore J: Skinfold Thicknesses and Measurement Technique. In Anthropometric Standardization Reference Manual 2nd edition. Edited by Lohman TG, Roche AF, Martorel R. 1988, 55-80.
• [33]Venter E, Gericke GJ, Bekker PJ: Nutritional status, quality of life and CD4 cell count of adults living with HIV/AIDS in the Ga-Rankuwa area (South Africa). S Afr J Clin Nutr 2009, 22:124-129.
• [34]Durnin JV, Womersley J: Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974, 32:77-97.
• [35]Sampaio LR, Simoes EJ, Assis AM, Ramos LR: Validity and reliability of the sagittal abdominal diameter as a predictor of visceral abdominal fat. Arq Bras Endocrinol Metabol 2007, 51:980-986.
• [36]Badia Llach X, Herdman M, Schiaffino A: Determining correspondence between scores on the EQ-5D “thermometer” and a 5-point categorical rating scale. Med Care 1999, 37:671-677.
• [37]Delate T, Coons SJ: The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis 2001, 32:E47-52.
• [38]Gakhar H, Kamali A, Holodniy M: Health-related quality of life assessment after antiretroviral therapy: a review of the literature. Drugs 2013, 73:651-672.
• [39]World Health Organization: Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection:Recommendations for a public health approach June 2013. Geneva: World Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf webcite
• [40]National Department of Health: Clinical Guidelines for the Management of HIV&AIDS in Adults and Adolescents. Pretoria: National Department of Health; 2010.
• [41]Mathews WC, May S: EuroQol (EQ-5D) measure of quality of life predicts mortality, emergency department utilization, and hospital discharge rates in HIV-infected adults under care. Health Qual Life Outcomes 2007, 5:5. BioMed Central Full Text
• [42]Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, Li X, Barnett PG, Joyce V, Swanson KM, Kyriakides TC, Holodniy M, Cameron DW, Brown ST, OPTIMA Team1: Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr 2009, 51:631-639.